Management and outcomes of patients undergoing high-risk oncologic pancreatic surgery: do patients presented at pancreatic multidisciplinary tumor board fare better?

Q3 Medicine

Baylor University Medical Center Proceedings Pub Date : 2026-11-01 Epub Date: 2026-08-19 DOI:10.1080/08998280.2026.2718630

Caroline Breit, Jacob Gibbs, Shalini Sharma, Ala Obaid, Charles Kimbrough, John Preskitt, Catherine Davis

{"title":"Management and outcomes of patients undergoing high-risk oncologic pancreatic surgery: do patients presented at pancreatic multidisciplinary tumor board fare better?","authors":"Caroline Breit, Jacob Gibbs, Shalini Sharma, Ala Obaid, Charles Kimbrough, John Preskitt, Catherine Davis","doi":"10.1080/08998280.2026.2718630","DOIUrl":null,"url":null,"abstract":"Background: Few studies have examined the impact of multidisciplinary tumor board (MDT) discussion on pancreatic cancer treatment and diagnosis. We aimed to determine whether these patients who are presented at MDT meetings have improved outcomes compared with those who are not presented.Methods: A retrospective chart review was performed of patients diagnosed with pancreatic cancer at our tertiary referral center between 2019 and 2022.Results: Of the 190 patients included in the study, 166 (87.4%) were presented at MDT. Patients presented were more likely to receive appropriate pretherapy workup (81.9% vs 37.5%, P < 0.001) and posttreatment surveillance (52.4% vs 20.8%, P = 0.004) and had fewer postoperative complications (30.7% vs 58.3%, P = 0.008) compared to patients who were not presented.Conclusion: All patients diagnosed with pancreatic cancer should be discussed at MDT meetings.","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":" ","pages":"947-951"},"PeriodicalIF":0.0000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13682239/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Baylor University Medical Center Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/08998280.2026.2718630","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Few studies have examined the impact of multidisciplinary tumor board (MDT) discussion on pancreatic cancer treatment and diagnosis. We aimed to determine whether these patients who are presented at MDT meetings have improved outcomes compared with those who are not presented.

Methods: A retrospective chart review was performed of patients diagnosed with pancreatic cancer at our tertiary referral center between 2019 and 2022.

Results: Of the 190 patients included in the study, 166 (87.4%) were presented at MDT. Patients presented were more likely to receive appropriate pretherapy workup (81.9% vs 37.5%, P < 0.001) and posttreatment surveillance (52.4% vs 20.8%, P = 0.004) and had fewer postoperative complications (30.7% vs 58.3%, P = 0.008) compared to patients who were not presented.

Conclusion: All patients diagnosed with pancreatic cancer should be discussed at MDT meetings.

查看原文本刊更多论文

高危胰腺肿瘤手术患者的管理和预后：在胰腺多学科肿瘤委员会上接受治疗的患者会更好吗？

背景：很少有研究探讨多学科肿瘤委员会（MDT）讨论对胰腺癌治疗和诊断的影响。我们的目的是确定与那些没有参加MDT会议的患者相比，参加MDT会议的患者是否有更好的预后。方法：对2019年至2022年在我院三级转诊中心诊断为胰腺癌的患者进行回顾性图表分析。结果：纳入研究的190例患者中，166例（87.4%）接受了MDT。与未就诊的患者相比，就诊的患者更有可能接受适当的治疗前随访（81.9% vs 37.5%, P = 0.004），术后并发症更少（30.7% vs 58.3%, P = 0.008）。结论：所有诊断为胰腺癌的患者都应在MDT会议上进行讨论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊